421 related articles for article (PubMed ID: 34768218)
41. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
42. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
[TBL] [Abstract][Full Text] [Related]
43. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
44. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
45. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
46. Determinants of response and resistance to CAR T cell therapy.
Lesch S; Benmebarek MR; Cadilha BL; Stoiber S; Subklewe M; Endres S; Kobold S
Semin Cancer Biol; 2020 Oct; 65():80-90. PubMed ID: 31705998
[TBL] [Abstract][Full Text] [Related]
47. Neurological Complications of CAR T Cell Therapy.
Landry K; Thomas AA
Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
[TBL] [Abstract][Full Text] [Related]
48. CAR-T cells: the Chinese experience.
Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H
Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454
[TBL] [Abstract][Full Text] [Related]
49. Challenges and optimal strategies of CAR T therapy for hematological malignancies.
Zhang Y; Xu Y; Dang X; Zhu Z; Qian W; Liang A; Han W
Chin Med J (Engl); 2023 Feb; 136(3):269-279. PubMed ID: 36848181
[TBL] [Abstract][Full Text] [Related]
50. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
Xiao X; Wang Y; Zou Z; Yang Y; Wang X; Xin X; Tu S; Li Y
Front Immunol; 2022; 13():954235. PubMed ID: 36091028
[TBL] [Abstract][Full Text] [Related]
51. Exhaustion of CAR T cells: potential causes and solutions.
Kouro T; Himuro H; Sasada T
J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821
[TBL] [Abstract][Full Text] [Related]
52. Updates on CAR T-cell therapy in B-cell malignancies.
Jacoby E; Shahani SA; Shah NN
Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492
[TBL] [Abstract][Full Text] [Related]
53. Progress on CAR-T cell therapy for hematological malignancies.
Hu K; Huang Y; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):192-203. PubMed ID: 36161291
[TBL] [Abstract][Full Text] [Related]
54. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
55. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
56. Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL).
Shouse G; Budde E; Forman S
Cancer Treat Res; 2021; 181():179-196. PubMed ID: 34626362
[TBL] [Abstract][Full Text] [Related]
57. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies.
Huang Y; Qin Y; He Y; Qiu D; Zheng Y; Wei J; Zhang L; Yang DH; Li Y
Drug Resist Updat; 2024 May; 74():101082. PubMed ID: 38569225
[TBL] [Abstract][Full Text] [Related]
58. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.
Baghery Saghchy Khorasani A; Yousefi AM; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109041. PubMed ID: 35839565
[TBL] [Abstract][Full Text] [Related]
59. CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Stem Cell Res Ther; 2021 Oct; 12(1):527. PubMed ID: 34620233
[TBL] [Abstract][Full Text] [Related]
60. Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review).
Poojary R; Song AF; Song BS; Song CS; Wang L; Song J
Mol Clin Oncol; 2023 Dec; 19(6):95. PubMed ID: 37920415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
